Tolerability of MenACWY-TT Vaccination in Toddlers in the Netherlands; A Questionnaire Study

Abstract Background: In May 2018, the monovalent MenC-TT conjugate vaccine given at 14 months of age within the National Immunization Programme in the Netherlands was replaced by a 4-valent MenACWY-TT conjugate vaccine. Methods: Results from a questionnaire about local reactions and systemic events within 4 days after vaccination were compared with data from a comparable tolerability study of a monovalent MenC-TT vaccine. Results: The response rate was 5.5% (1157/20966 questionnaires). Any local reaction was reported for 3.7% of the toddlers, with the highest percentage found for local redness at the injection site (2.9%). Any systemic event was reported for 32.4% of the toddlers, with listlessness (22.4%) most often reported. Fever was the only symptom more frequently reported after MenACWY-TT vaccination compared with MenC-TT vaccination (adj OR 1.61; 95% CI 1.29-2.01).Conclusions: the 4-valent MenACWY-TT vaccine showed to be a little more reactogenic compared with to the monovalent MenC-TT vaccine, with a higher risk of fever within 4 days after vaccination. For the other factors no increased risks were found. Overall, this study shows that MenACWY-TT vaccination is well tolerated in toddlers.

Download Full-text

Economic Impact of Pneumococcal Protein-D Conjugate Vaccine (PHiD-CV) on the Malaysian National Immunization Programme

Value in Health Regional Issues ◽

10.1016/j.vhri.2014.04.008 ◽

2014 ◽

Vol 3 ◽

pp. 146-155 ◽

Cited By ~ 10

Author(s):

Syed Aljunid ◽

Namaitijiang Maimaiti ◽

Zafar Ahmed ◽

Amrizal Muhammad Nur ◽

Zaleha Md Isa ◽

...

Keyword(s):

Economic Impact ◽

Conjugate Vaccine ◽

Immunization Programme ◽

National Immunization ◽

National Immunization Programme

Download Full-text

Corrigendum to “Cost-effectiveness of introducing a domestic pneumococcal conjugate vaccine (PCV7-TT) into the Cuban national immunization programme” [Int. J. Infect. Dis. 97 (2020) 182–189]

International Journal of Infectious Diseases ◽

10.1016/j.ijid.2020.08.072 ◽

2020 ◽

Author(s):

Anai García Fariñas ◽

Nivaldo Linares-Pérez ◽

Andrew Clark ◽

María Eugenia Toledo-Romaní ◽

Nathalie El Omeiri ◽

...

Keyword(s):

Cost Effectiveness ◽

Conjugate Vaccine ◽

Pneumococcal Conjugate Vaccine ◽

Immunization Programme ◽

National Immunization ◽

National Immunization Programme

Download Full-text

Tolerability of MenACWY-TT vaccination in adolescents in the Netherlands; a cross-sectional study

BMC Public Health ◽

10.1186/s12889-021-11767-9 ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

J. M. Kemmeren ◽

L. van Balveren ◽

A. Kant ◽

H. de Melker

Keyword(s):

The Netherlands ◽

Adverse Events ◽

Sample Size Calculation ◽

Cross Sectional Study ◽

Cross Sectional ◽

Immunization Programme ◽

National Immunization ◽

National Immunization Programme ◽

Before And After ◽

Systemic Symptoms

Abstract Background In 2018, meningococcal ACWY-TT vaccine (MenACWY-TT) was offered to adolescents in the Netherlands within the National Immunization Programme at 14 years of age. A questionnaire study assessed the tolerability of this vaccine. Methods Five thousand adolescents were invited to participate and to fill in two questionnaires about systemic events in the week before vaccination and local reactions and systemic events in the week after vaccination. Frequencies of local and systemic adverse events in the week after vaccination were calculated. Association between the occurrence of systemic symptoms in the week before and after the vaccination was tested by using generalized mixed models (GLMM). Results Of all adolescents, 139 returned one or both questionnaires. Any local reaction within 7 days after vaccination was reported by 55.6% of the adolescents. Pain (50%) and reduced use of the injected arm (21.3%) were most often reported. Any systemic event was reported by 67.6% of the participants, with myalgia as the most often reported event (37.0%). Compared with the week before vaccination, there were no increased odds of experiencing systemic symptoms in the week after vaccination (OR 0.95; 95%CI 0.40–2.27). Conclusions After vaccination with MenACWY-TT vaccine, most adolescents reported one or more adverse events, which were mostly mild and transient. Systemic symptoms were not reported more often in the week after compared to the week before vaccination. Unfortunately, due to a low response rate we were not able to detect the absolute elevated risks the sample size calculation was based on. However, despite limited data, our results are in line with results from prelicensure data, and indicate that MenACWY-TT vaccination is well tolerated in adolescents.

Download Full-text

Low seroprevalence of Q fever in The Netherlands prior to a series of large outbreaks

Epidemiology and Infection ◽

10.1017/s0950268811000136 ◽

2011 ◽

Vol 140 (1) ◽

pp. 27-35 ◽

Cited By ~ 31

Author(s):

B. SCHIMMER ◽

D. W. NOTERMANS ◽

M. G. HARMS ◽

J. H. J. REIMERINK ◽

J. BAKKER ◽

...

Keyword(s):

The Netherlands ◽

Q Fever ◽

Epidemiological Data ◽

Age Group ◽

Phase 2 ◽

Immunization Programme ◽

National Immunization ◽

National Immunization Programme ◽

Independent Risk Factors ◽

Community Outbreaks

SUMMARYThe Netherlands has experienced large community outbreaks of Q fever since 2007. Sera and questionnaires containing epidemiological data from 5654 individuals were obtained in a nationwide seroprevalence survey used to evaluate the National Immunization Programme in 2006–2007. We tested these sera for IgG phase-2 antibodies against Coxiella burnetii with an ELISA to estimate the seroprevalence and to identify determinants for seropositivity before the Q fever outbreaks occurred. Overall seroprevalence was 1·5% [95% confidence interval (CI) 1·3–1·7]. Corrected for confirmation with immunofluorescence results in a subset, the estimated seroprevalence was 2·4%. Seropositivity ranged from 0·48% (95% CI 0·00–0·96) in the 0–4 years age group to 2·30% (95% CI 1·46–3·15) in the 60–79 years age group. Keeping ruminants, increasing age and being born in Turkey were independent risk factors for seropositivity. The low seroprevalence before the start of the outbreaks supports the hypothesis that The Netherlands has been confronted with a newly emerging Q fever problem since spring 2007.

Download Full-text